Document Detail


Update in the treatment of venous thromboembolism.
MedLine Citation:
PMID:  18302085     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This review describes recent evidence relevant to the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Because venous thromboembolism (VTE) is a spectrum of disease that includes both of these disorders, many of the therapeutic options are common to both. At the time of diagnosis, effective treatment options for patients with VTE include unfractionated heparin, low molecular weight heparins (e.g., dalteparin, enoxaparin, tinzaparin), and pentasaccharides (e.g., fondaparinux). Many patients with VTE, especially DVT, can receive most or all of their initial treatment as outpatients. Other treatment strategies such as vena caval filter placement and mechanical (or chemical) clot dissolution are discussed briefly. Anticoagulation with warfarin (or other oral vitamin K antagonists) is a highly effective strategy for the long-term prevention of VTE recurrence in most patients. In addition to presenting evidence relevant to the optimal duration of warfarin therapy, we highlight circumstances under which extended therapy with a parenteral agent such as a low molecular weight heparin might be preferable.
Authors:
David A Garcia; Alex C Spyropoulos
Related Documents :
15971115 - Explicit versus implicit risk assessment for the indication of antithrombotic prophylax...
616155 - Combined thrombectomy and isolated limb perfusion with streptokinase in the treatment o...
22440935 - Effective method to remove wound bacteria: comparison of various debridement modalities...
12422105 - The effect of external pneumatic compression on regional fibrinolysis in a prospective ...
3197445 - Steatocystoma multiplex treated with isotretinoin: a delayed response.
19261555 - Gum chewing reduces postoperative ileus? a systematic review and meta-analysis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in respiratory and critical care medicine     Volume:  29     ISSN:  1069-3424     ISO Abbreviation:  Semin Respir Crit Care Med     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-27     Completed Date:  2008-06-17     Revised Date:  2009-06-13    
Medline Journal Info:
Nlm Unique ID:  9431858     Medline TA:  Semin Respir Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  40-6     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA. davgarcia@salud.unm.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Pulmonary Embolism / drug therapy*
Venous Thromboembolism / drug therapy*
Venous Thrombosis / drug therapy*
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 81-81-2/Warfarin
Comments/Corrections
Erratum In:
Semin Respir Crit Care Med. 2008 Jun;29(3):319
Note: Dosage error in article text

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thrombophilias: when should we test and how does it help?
Next Document:  Massive pulmonary embolism: what level of aggression?